AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
This article was originally published in PharmAsia News
In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
You may also be interested in...
AstraZeneca agreed to pay $260 million plus contingency payments to acquire Omthera, the makers of the omega-3 product Epanova, which is ready for regulatory filing for dyslipidemia. The deal raises questions for Amarin, whose similar product Vascepa has reached the market without a big pharma partner.
AstraZeneca’s biologics unit MedImmune acquired AlphaCore Pharma, the developer of an early-stage asset with a novel mechanism for removing cholesterol from the body and raising “good” HDL cholesterol.
AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.